FOUNDED IN OCTOBER 2018 BY PROFESSOR BENGT SAMUELSSON, A NOBEL PRICE LAUREATE, PROFESSOR JAN-CHRISTER JANSON, DR. GU MING AND HER TEAM. ENLITISA IS A CHINESE-SWEDISH COMPANY FOCUSED ON DEVELOPING TREATMENTS FOR INFLAMMATORY AND FIBROTIC DISEASES WITH HIGH UNMET MEDICAL NEED
Improving lives for patients with serious inflammatory and fibrotic diseases
EnliTISA
About EnliTISA
Founded in
International invention patents
R & D Innovation
Our team


Potter Clarkson Intellectual Property Office, UK
· Has cooperated with the company for 5 and a half years, responsible for the company's intellectual property strategy construction and international PCT application, completed 12 international invention patent applications, 2 Chinese patent authorizations, and 1 US patent authorization. IP due diligence and negotiation to support Chinese and overseas transactions · Supported over 70 clients in IP due diligence and negotiation of intercontinental licensing transactions
The world's leading original innovative
drug enterprise for inflammation and injury
News
The world's leading original innovative drug enterprise for inflammation and injury
Tel:+86-021-33758853
Add:Room 201, 202, 203, BuildingA, Block1, No. 800, Qingdai Road, Pudong New District, Shanghai
Copyright ©2022 EnliTISA (Shanghai) Pharmaceutical Co., Ltd. | SEO 沪ICP备2022023966号-1 Powered by www.300.cn